Home   >  
Ion Channel/Membrane Transporter

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
VX-659 Chemical Structure
BCP29456 VX-659 2204245-48-5
VX-659 is a CFTR protein inhibitor.
ABBV-2222 Chemical Structure
BCP25130 ABBV-2222 1918143-53-9
ABBV-2222, also known as GLPG2222, is a CFTR corrector being studied for the treatment of cystic fibrosis (CF).
VX-661 Chemical Structure
BCP07173 VX-661 1152311-62-0
A Phase II study is developing with VX-661 to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) effects of VX-661 alone and when coadministered with VX-770 in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del-CFTR mutation.
KM 11060 Chemical Structure
BCP17185 KM 11060 774549-97-2
KM11060 is a mutated F508del cystic fibrosis transmembrane conductance regulator (CFTR) corrector.
GLPG1837 Chemical Structure
BCP23611 GLPG1837 1654725-02-6
A potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively; shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor.
CFTRinh-172 Chemical Structure
BCP15834 CFTRinh-172 307510-92-5
CFTR(inh)-172 is an reversibly inhibitor of CFTR short-circuit current in less than 2 minutes in a voltage-independent manner with Ki approximately 300 nM.
Ataluren Chemical Structure
BCP01756 Ataluren 775304-57-9
PTC124 is CFTR-G542X nonsense allele inhibitor.
Ivacaftor hydrate Chemical Structure
BCP14735 Ivacaftor hydrate 1134822-07-3
Ivacaftor hydrate (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.
Ivacaftor benzenesulfonate Chemical Structure
BCP19043 Ivacaftor benzenesulfonate 1134822-09-5
Ivacaftor benzenesulfonate (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.
VX-809 Chemical Structure
BCP02305 VX-809 936727-05-8
VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
12下一页共 13 条记录 1 / 2 页